Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study
Annweiler et al.,
Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The..,
Nutrients, doi:10.3390/nu12113377
Retrospective study finding that regular bolus vitamin D supplementation was associated with less severe COVID-19 and better survival in frail elderly.
For those receiving regular supplementation:
Adjusted mortality hazard ratio with supplementation HR 0.07,
p = 0.017.
Risk of severe COVID-19 with supplementation OR 0.08,
p = 0.033.
For supplementation started after COVID-19 diagnosis:
Adjusted mortality hazard ratio HR 0.37,
p = 0.28.
Risk of severe COVID-19 with supplementation OR 0.46,
p = 0.4.
risk of death, 93.0% lower, RR 0.07, p = 0.02, treatment 2 of 29 (6.9%), control 10 of 32 (31.2%), NNT 4.1, adjusted per study, regular bolus supplementation.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Annweiler et al., 2 Nov 2020, retrospective, France, peer-reviewed, mean age 88.0, 7 authors, dosage 50,000IU monthly, dose varies - 50,000 IU/month, or 80,000IU/100,000IU every 2–3 months.
Abstract: nutrients
Article
Vitamin D Supplementation Associated to Better
Survival in Hospitalized Frail Elderly COVID-19
Patients: The GERIA-COVID
Quasi-Experimental Study
Gaëlle Annweiler 1,2 , Mathieu Corvaisier 3,4 , Jennifer Gautier 3 , Vincent Dubée 1,5,6 ,
Erick Legrand 1,7 , Guillaume Sacco 3,8 and Cédric Annweiler 1,3,8,9,10, *
on behalf of the GERIA-COVID study group
1
2
3
4
5
6
7
8
9
10
*
School of Medicine, Health Faculty, University of Angers, 49045 Angers, France;
gaelle.annweiler@gmail.com (G.A.); Vincent.Dubee@chu-angers.fr (V.D.); ErLegrand@chu-angers.fr (E.L.)
Department of Medicine, Clinique de l’Anjou, 49044 Angers, France
Department of Geriatric Medicine, Research Center on Autonomy and Longevity, University Hospital,
49933 Angers, France; Mathieu.Corvaisier@chu-angers.fr (M.C.); JeGautier@chu-angers.fr (J.G.);
yogisacco@gmail.com (G.S.)
Department of Pharmacy, Angers University Hospital, 49933 Angers, France
Nantes-Angers Cancer and Immunology Research Center (CRCINA), Inserm, University of Angers,
49000 Angers, France
Department of Infectious and Tropical Diseases, Angers University Hospital, 49933 Angers, France
Department of Rheumatology, Angers University Hospital, 49933 Angers, France
EA4638, Laboratory of Psychology of the Pays de la Loire, University of Angers, 49045 Angers, France
Gérontopôle of Pays de la Loire, 44000 Nantes, France
Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry,
the University of Western Ontario, London, ON N6A 5K8, Canada
Correspondence: Cedric.Annweiler@chu-angers.fr; Tel.: +332-4135-4725; Fax: +332-4135-4894
Received: 23 September 2020; Accepted: 28 October 2020; Published: 2 November 2020
Abstract: Background. The objective of this quasi-experimental study was to determine whether
bolus vitamin D supplementation taken either regularly over the preceding year or after the diagnosis
of COVID-19 was effective in improving survival among hospitalized frail elderly COVID-19 patients.
Methods. Seventy-seven patients consecutively hospitalized for COVID-19 in a geriatric unit were
included. Intervention groups were participants regularly supplemented with vitamin D over the
preceding year (Group 1), and those supplemented with vitamin D after COVID-19 diagnosis (Group
2). The comparator group involved participants having received no vitamin D supplements (Group 3).
Outcomes were 14-day mortality and highest (worst) score on the ordinal scale for clinical improvement
(OSCI) measured during COVID-19 acute phase. Potential confounders were age, gender, functional
abilities, undernutrition, cancer, hypertension, cardiomyopathy, glycated hemoglobin, number of
acute health issues at admission, hospital use of antibiotics, corticosteroids, and pharmacological
treatments of respiratory disorders. Results. The three groups (n = 77; mean ± SD, 88 ± 5 years; 49%
women) were similar at baseline (except for woman proportion, p = 0.02), as were the treatments used
for COVID-19. In Group 1 (n = 29), 93.1% of COVID-19 participants survived at day 14, compared to
81.2% survivors in Group 2 (n = 16) (p = 0.33) and 68.7% survivors in Group 3 (n = 32) (p = 0.02). While
considering Group 3 as reference (hazard ratio (HR) = 1), the fully-adjusted HR for 14-day mortality
was HR = 0.07 (p = 0.017) for Group 1 and HR = 0.37 (p = 0.28) for Group 2. Group 1 had longer
survival time than Group 3 (log-rank p = 0.015), although there was no..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit